Oncology A quarter of cancer patients don’t respond to targeted thera... The more progress we make in precision medicine, the more edge cases we discover.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
News GSK sets up Nucala and Dupixent showdown in COPD GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
